Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework

White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example

(2022) Christian Jackisch et al.   ADVANCES IN THERAPY

Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?

(2022) Christophe Maritaz et al.   Journal of Hematology & Oncology

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

(2022) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rural Transportation Infrastructure in Low- and Middle-Income Countries: A Review of Impacts, Implications, and Interventions

(2022) Noah Kaiser et al.   Sustainability

Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications

(2022) Mihajlo Jakovljevic et al.   Health Research Policy and Systems

The current paradigm for biologic initiation: a confirmatory quantitative analysis of self-injection training practices

(2022) James Hawthorne et al.   Expert Opinion on Drug Delivery

It is Never Too Late for a Cocktail - Development and Analytical Characterization of Fixed-dose Antibody Combinations

(2022) Dennis Krieg et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Editorial: Emerging Markets’ Health and Pharmaceutical Sectors at the Dawn of a Potential Global Financial Crisis of early 2020s

(2022) Mihajlo Jakovljevic et al.   Frontiers in Pharmacology

Patient and Clinician Attitudes Towards Telemedicine for Allergy and Immunology

(2022) Allison Ramsey et al.   Journal of Allergy and Clinical Immunology-In Practice

Health supply chain system in Uganda: current issues, structure, performance, and implications for systems strengthening

(2022) Eric Lugada et al.   Journal of Pharmaceutical Policy and Practice

High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries

(2021) Barbara Bortone et al.   PLoS One

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma

(2021) Larysa Sanchez et al.   Therapeutic Advances in Hematology

Inhaled fixed-dose combination powders for the treatment of respiratory infections

(2021) Ashlee D. Brunaugh et al.   Expert Opinion on Drug Delivery

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

(2021) Sherko Kuemmel et al.   BREAST CANCER RESEARCH AND TREATMENT

Digital Health Integration Assessment and Maturity of the United States Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Autoinjectable Devices

(2021) Ramin Rafiei et al.   JMIR mHealth and uHealth

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

(2021) Joyce O'Shaughnessy et al.   EUROPEAN JOURNAL OF CANCER

Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors

(2021) Alex Abramson et al.   NATURE BIOTECHNOLOGY

Economic Evaluations of Breast Cancer Care in Low‐ and Middle‐Income Countries: A Scoping Review

(2021) Parsa Erfani et al.   ONCOLOGIST

Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures

(2021) Christel Larbouret et al.   Cancers

Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices

(2021) Liese Barbier et al.   Pharmaceuticals

Mobile app validation: a digital health scorecard approach

(2021) Ramy Sedhom et al.   npj Digital Medicine

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs

(2021) Robert S Epstein   ClinicoEconomics and Outcomes Research

Toward Automated Support of Complaint Handling Processes: An Application in the Medical Technology Industry

(2021) Philip Hake et al.   Journal on Data Semantics

Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?

(2021) W Jiskoot et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy

(2021) Giuseppe Argenziano et al.   Patient Preference and Adherence

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

(2020) MAURIEN D. ROMBOUTS et al.   ANTICANCER RESEARCH

BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT®

(2020) Francesco Patti et al.   Patient Preference and Adherence

Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review

(2020) Graham Walter et al.   Allergy Asthma and Clinical Immunology

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

(2020) Antoinette R Tan et al.   LANCET ONCOLOGY

A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience

(2019) Bart J. F. van den Bemt et al.   DRUG DELIVERY

Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma

(2019) Saad Z. Usmani et al.   BLOOD

Value-Based Provider Payment Initiatives Combining Global Payments With Explicit Quality Incentives: A Systematic Review

(2019) Daniëlle Cattel et al.   MEDICAL CARE RESEARCH AND REVIEW

Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis

(2018) Lisa W. Fu et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

(2018) Marie Viala et al.   BRITISH JOURNAL OF CANCER

Tutorial on Monoclonal Antibody Pharmacokinetics and its Considerations in Early Development

(2018) Meric Ovacik et al.   CTS-Clinical and Translational Science

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients

(2018) Boris Bienvenu et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Key strategies to improve systems for managing patient complaints within health facilities – what can we learn from the existing literature?

(2018) Tolib Mirzoev et al.   Global Health Action

Digital Health Intervention for Asthma: Patient-Reported Value and Usability

(2018) Rajan Merchant et al.   JMIR mHealth and uHealth

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

(2018) Beate Bittner et al.   BIODRUGS

Three pillars of sustainability: in search of conceptual origins

(2018) Ben Purvis et al.   Sustainability Science

Home-Based Treatment with Immunoglobulins: an Evaluation from the Perspective of Patients and Healthcare Professionals

(2018) Chantal A. Zuizewind et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study

(2018) Whitney P. Kirschbrown et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases

(2017) Richard L Wasserman   Immunotherapy

Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis

(2017) David T. Rubin et al.   Journal of Managed Care & Specialty Pharmacy

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

(2016) M. Rummel et al.   ANNALS OF ONCOLOGY

Fee-For-Service, While Much Maligned, Remains The Dominant Payment Method For Physician Visits

(2016) Samuel H. Zuvekas et al.   HEALTH AFFAIRS

A novel electromechanical autoinjector, AutoTouch™, for self-injection of etanercept: real-world use and benefits

(2016) David H. Collier et al.   POSTGRADUATE MEDICINE

Analysis of Fixed-Dose Combination Products Approved by the US Food and Drug Administration, 2010-2015

(2016) Kyu Chan Kwon et al.   Therapeutic Innovation & Regulatory Science

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting

(2016) Ricardo Dent et al.   SpringerPlus

Misuse of Autoinjectors and Inhalers

(2015) Carol Potera   AMERICAN JOURNAL OF NURSING

Assessments of antibody biodistribution

(2015) Patrick M. Glassman et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Hyaluronidase-incorporated hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab

(2015) Keming Xu et al.   JOURNAL OF CONTROLLED RELEASE

Using Electronic Monitoring Devices to Measure Inhaler Adherence: A Practical Guide for Clinicians

(2015) Amy Hai Yan Chan et al.   Journal of Allergy and Clinical Immunology-In Practice

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

(2014) Andrew Davies et al.   LANCET ONCOLOGY

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Metrics for the Evaluation of Bioequivalence of Modified-Release Formulations

(2012) Laszlo Endrenyi et al.   AAPS Journal

RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence

(2012) Alessandra Lugaresi   Expert Opinion on Drug Delivery

Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

(2012) Richard L. Wasserman   JOURNAL OF CLINICAL IMMUNOLOGY

Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer

(2012) Chris Wynne et al.   JOURNAL OF CLINICAL PHARMACOLOGY

CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer

(2010) José Baselga et al.   Clinical Breast Cancer

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

(2010) John B. Hagan et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Review of the Safety and Feasibility of Rapid Infusion of Rituximab

(2010) Jill Atmar   Journal of Oncology Practice